Introduction
The FDA chlorthalidone recall now covers 13,567 bottles of 25 mg chlorthalidone tablets manufactured by Inventia Healthcare Limited after the tablets failed required dissolution specifications. The FDA classified the recall as Class II on September 17, 2026.
The affected medicine is a prescription diuretic commonly used to treat high blood pressure. The recalled lot involves 100-tablet bottles with NDC 64980-599-01, batch RISA24002 and an expiration date of April 2027.
The important distinction is that this is a recall of a specific lot, not a recall of every chlorthalidone product.
Background and Context
Chlorthalidone is a thiazide-like diuretic, sometimes called a water pill. It helps the kidneys remove salt and water from the body, which can reduce blood pressure and fluid retention.
The current recall was initiated voluntarily by Inventia Healthcare on September 3, 2026. The FDA subsequently classified it as Class II.
The FDA’s Class II designation covers situations where use or exposure may cause temporary or medically reversible adverse health consequences, or where the probability of serious consequences is considered remote.
This is also not the first chlorthalidone recall involving dissolution specifications in 2026. A separate June recall involved approximately 11,460 bottles of 25 mg chlorthalidone distributed by Risiong Pharma Holdings. That earlier action involved different batches.
Latest Update: What the FDA Chlorthalidone Recall Covers
The current FDA chlorthalidone recall involves:
- Medication: Chlorthalidone Tablets, USP
- Strength: 25 mg
- Bottle size: 100 tablets
- NDC: 64980-599-01
- Batch: RISA24002
- Expiration: 04/2027
- Manufacturer: Inventia Healthcare Limited
- Distribution: Nationwide in the United States
- Quantity: Approximately 13,567 bottles
- Recall classification: Class II
- Reason: Failed dissolution specifications
The FDA’s dissolution standards exist to help establish that an oral drug releases its active ingredient appropriately from the dosage form. The agency explains that dissolution testing is used to evaluate how drug substance is released from tablets and other dosage forms.
That matters because a dissolution failure can potentially affect how much of the active ingredient becomes available for absorption.
Importantly, the publicly reported recall information does not establish that every tablet in the affected batch will fail in the same way or that every patient taking one will experience an adverse effect.
How to Check Your Bottle
Patients taking chlorthalidone can compare the information on their prescription bottle with the recalled-product details.
The most important identifiers are:
RISA24002 + NDC 64980-599-01 + 25 mg + expiration 04/2027.
If the information does not match completely, the product should not automatically be assumed to be part of this particular recall.
The FDA recommends checking the lot number when determining whether a medicine has been recalled.
What “Failed Dissolution Specifications” Means
The phrase sounds technical, but the basic concept is straightforward.
A tablet has to release its active ingredient in a predictable way after it is taken. Dissolution testing evaluates that release under controlled laboratory conditions.
The FDA notes that its dissolution methods are used to help assess drug products and their release characteristics. For many oral medicines, testing is conducted under standardized conditions designed to model relevant aspects of drug release.
A failure does not necessarily mean the tablet contains no active ingredient. Rather, it means the product did not meet the specified dissolution requirement.
For a medication used to control blood pressure, reduced or inconsistent drug release could potentially affect treatment effectiveness. That is why the affected lot has been removed from distribution.
Expert Insights and Medical Analysis
The available recall information provides a quality-based explanation, rather than evidence of a widespread clinical problem.
Good Housekeeping reports that the FDA’s September recall involved more than 13,000 bottles and that the agency classified it as Class II. It also advises patients not to independently stop or change their medication because of the recall.
That point is important for people taking chlorthalidone for hypertension. Blood-pressure treatment decisions should account for the individual’s condition and other medications.
The FDA’s general guidance on drug recalls says consumers should check their medication’s lot number against the recall information and work with their healthcare provider or pharmacist if their product is affected.
There is therefore a practical distinction between checking a bottle and changing treatment. The first can be done by comparing the product identifiers. The second should be discussed with a healthcare professional.
Broader Implications
For Patients Taking Chlorthalidone
The immediate issue is identification.
Not every chlorthalidone tablet is part of the current recall. The specific NDC, batch number and expiration date matter.
If a bottle matches the recalled product, patients should contact their pharmacist or prescribing healthcare professional for instructions about replacement and treatment.
The FDA specifically advises consumers to check the lot number when determining whether their medicine is affected by a recall.
For Drug Manufacturing
The recall highlights why dissolution testing matters for solid oral medicines.
A tablet can contain the correct active pharmaceutical ingredient yet still fail a quality specification involving how that ingredient is released.
FDA documentation on dissolution testing explains that the agency uses standardized methods and acceptance criteria to assess drug-product performance.
For Drug Recall Monitoring
The episode also demonstrates why recall classifications can change after a manufacturer initiates an action.
FDA says a company may voluntarily initiate a recall, while the agency oversees the recall strategy and can classify the action according to the potential hazard.
For readers following pharmaceutical safety news, this distinction is useful: an announcement that a company has recalled a product and a subsequent FDA classification are related but separate stages of the regulatory process.
For additional health and technology coverage, an internal link could point readers toward The Tech Marketer’s health-tech and pharmaceutical technology coverage at The Tech Marketer.
Related History or Comparable Recalls
The current recall follows another chlorthalidone recall announced earlier in 2026.
The June action involved approximately 11,460 bottles of 25 mg chlorthalidone. Those products included batch RISA24001 in 100-count bottles and batch RISB24002 in 1,000-count bottles, with an April 2027 expiration date. A recall notice published by the California Board of Pharmacy said testing found both an assay result below the approved specification and dissolution results below the required acceptance criterion.
The September action is different.
It involves batch RISA24002, a 100-count bottle and NDC 64980-599-01.
That means patients should not assume that every product from the manufacturer, or every chlorthalidone bottle, is automatically included.
What Happens Next
The current recall remains an active issue for the affected product.
Patients should compare their prescription information with the recalled identifiers and contact a pharmacist or healthcare professional if there is a match.
The FDA’s general drug-recall guidance says consumers can learn about recalls through FDA announcements, manufacturers, healthcare providers and pharmacies. It also recommends checking the lot number against the recall notice.
The FDA maintains a drug-recall resource where consumers can find recall information and distinguish ongoing recalls from terminated actions.
For anyone who experiences concerning symptoms or believes they have experienced a medication-related problem, medical advice should come from a qualified healthcare professional. Medication changes should not be made solely on the basis of social-media posts or generalized recall coverage.
Conclusion
The FDA chlorthalidone recall affects a specific batch of 25 mg tablets manufactured by Inventia Healthcare, not all chlorthalidone medications.
The recalled product is identified by NDC 64980-599-01, batch RISA24002 and an April 2027 expiration date. Approximately 13,567 bottles are involved, and the FDA has classified the action as Class II because of failed dissolution specifications.
For patients, the key step is straightforward: check the bottle against the recall identifiers. If it matches, contact a pharmacist or prescribing healthcare professional before making changes to treatment.
FAQ
1. What is the FDA chlorthalidone recall?
The FDA chlorthalidone recall involves approximately 13,567 bottles of 25 mg chlorthalidone tablets from one affected batch. The recall was initiated by Inventia Healthcare and classified by the FDA as Class II.
2. Which chlorthalidone lot has been recalled?
The current September 2026 recall involves batch RISA24002, NDC 64980-599-01, 100-tablet bottles of 25 mg tablets with an expiration date of 04/2027.
3. Why was chlorthalidone recalled?
The tablets failed dissolution specifications. This means the affected product did not meet the required testing standard for how the active ingredient is released from the tablet.
4. Is every chlorthalidone tablet recalled?
No. The current action concerns a specific product configuration and batch. Patients should compare the NDC, batch number, strength and expiration date on their bottle with the recall information.
5. Should I stop taking recalled chlorthalidone?
Patients should not independently stop or change a prescription blood-pressure medication. If the bottle matches the recalled product, contact a pharmacist or prescribing healthcare professional for individualized instructions.
6. What does an FDA Class II recall mean?
The FDA describes a Class II recall as a situation where use or exposure may cause temporary or medically reversible adverse health consequences, or where the probability of serious consequences is considered remote.
7. Is this the first chlorthalidone recall in 2026?
No. A separate June 2026 recall involved approximately 11,460 bottles of 25 mg chlorthalidone with different batch numbers.
8. Where can patients check drug recall information?
The FDA maintains a drug-recall resource containing recall announcements and information about recall status.
